While CD38 and SLAMF7 were detected at high levels on the surface of virtually all myeloma cells even in heavily pretreated patients, we found heterogeneous BCMA expression with substantial inter- and intra-individual differences and the regular occurrence of BCMA-negative subpopulations (Fig. 1b). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.